Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30141105 | 1.00 | KMT2A (0.62) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL873776 | 0.91 | SMPD1 (0.70) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL2087641 | 0.91 | NPC1 (0.71) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL2706286 | 0.90 | KMT2A (0.54) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL4403626 | 0.90 | SMN1; SMN2 (0.61) | KMT2ALMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10861035 | 0.89 | SMN1; SMN2 (0.63) | KMT2ALMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17289269 | 0.88 | NPC1 (0.53) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL3960881 | 0.88 | LMNA (0.62) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL22015271 | 0.88 | LMNA (0.62) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL1647432 | 0.88 | TDP1 (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-04-17 | — | — | US | disclosed |
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4410774-A1 | ANTIBACTERIAL COMPOSITION | Seoul National University R&DB Foundation (KR) | 2024-08-07 | — | — | EP | disclosed |
| EP-4370113-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | Avanti Biosciences Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023048337-A1 | ANTIBACTERIAL COMPOSITION | 서울대학교산학협력단 | 2023-03-30 | — | — | WO | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2019071351-A1 | NOVEL FLUORINATED 4-ARYLOXYQUINAZOLINE DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-04-18 | — | — | WO | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2013062762-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2013-05-02 | — | — | WO | disclosed |
| US-7589170-B1 | Synthesis of cyclic peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SQSTM1, BECN1, ATG7 | KMT2A 3655/4885TDP1 4598/4885SLC6A2 3342/4885 |
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | MPO, GPX4, GPX1 | KMT2A 4001/4885TDP1 1665/4885SLC6A2 4311/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | KMT2A 4291/4885TDP1 4219/4885SLC6A2 3853/4885 |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | KMT2A 3139/4885TDP1 428/4885SLC6A2 143/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | KMT2A 3652/4885TDP1 4080/4885SLC6A2 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.